E-Z-EM Receives Additional Order for RSDL from U.S. Department of Defense

  
    
  
  
    
      E-Z-EM, Inc. (NASDAQ:EZEM) today announced that the U.S. Army 
      Space & Missile Defense Command (USASMD) has placed an additional order 
      for the Company’s RSDLTM 
      personal skin decontamination product. The approximately $8 million 
      order is the second such order placed by the U.S. Department of Defense 
      (DoD) since it issued Milestone C approval for the product, and is the 
      largest single order for RSDL the Company has received to date. The 
      Company expects to ship and invoice for the order by April 2008 with 
      resulting revenues recognized as the product is shipped.
    
    
      Commenting on the announcement, Anthony A. Lombardo, President and CEO 
      of E-Z-EM, said, “We are especially pleased 
      with this order as the DoD has exceeded our original estimate for 
      procurement of RSDL in the government’s 2007 
      fiscal year. Additionally, we are pleased the DoD placed this follow-on 
      order so quickly after their initial procurement of RSDL in March of 
      2007. We believe this demonstrates the importance with which the DoD 
      views RSDL and its ability to provide our troops with improved 
      protection against chemical weapons agents.”
    
    
      About RSDL
    
    
      RSDL is a patented, broad spectrum skin decontamination product intended 
      to remove or neutralize chemical warfare (CW) agents or T2 toxins from 
      the skin. RSDL was originally developed and patented by Defence Research 
      and Development Canada, an agency within the Canadian Department of 
      National Defence, for use by the Canadian Forces. RSDL has since been 
      adopted by several military services around the world. RSDL is produced 
      by EZEM under a License with Defence Research and Development Canada 
      (DRDC). RSDL has since been adopted by several military services around 
      the world.
    
    
      RSDL received Milestone C approval from the Joint Program Executive 
      Office for Chemical Biological Defense (JPEO-CBD), a decision that 
      cleared the way for procurement by the individual service branches of 
      the DoD. The US Food and Drug Administration (FDA) issued 510(k) 
      clearance for RSDL in March of 2003. The U.S. DoD began final 
      configuration testing on the product in November of 2003 and authorized 
      the sale of RSDL to first responder organizations in September of 2004. 
      In September 2006, RSDL was awarded Safety Act certification by the U.S. 
      Department of Homeland Security (DHS), which extends certain liability 
      protections to the Company and its suppliers and customers (whether 
      public or private) in the event RSDL is used in response to a terrorist 
      incident.
    
    
      About E-Z-EM, Inc.
    
    
      E-Z-EM is a publicly traded healthcare company founded in 1962, and has 
      since established itself as one of the most recognized brands in 
      diagnostic imaging of the GI tract. From the first barium contrast 
      systems introduced over 40 years ago, to today's advanced products for 
      CT imaging and virtual colonoscopy, E-Z-EM has continually developed 
      innovative imaging and diagnostic solutions for physicians treating GI 
      diseases. E-Z-EM is also a respected contract manufacturer of 
      specialized liquid products, and has been the exclusive global 
      manufacturer of RSDL™ since 1996. In April of 
      2005, E-Z-EM completed the acquisition of all assets associated with 
      RSDL, and now is the product's exclusive worldwide marketer to 
      first-responder organizations and military services.
    
    
      The statements made in this document contain certain forward-looking 
      statements. Words such as “expects,” 
      “intends,” “anticipates,” 
      “plans,” “believes,” 
      “seeks,” “estimates” 
      or variations of such words and similar expressions, are intended to 
      identify such forward-looking statements. The forward-looking statements 
      contained in this release may involve numerous risks and uncertainties, 
      known and unknown, beyond the Company’s 
      control. Such risks and uncertainties include: the ability of the 
      Company to develop its products, placement of further DoD orders for 
      RSDL, the timing of revenue recognition for RSDL and its impact on the 
      Company's financial results, the impact on future sales of SAFETY Act 
      designation and certification for RSDL, future orders of RSDL by first 
      responder organizations, general military and first-responder market 
      acceptance and sales of RSDL, future actions by the FDA or other 
      regulatory agencies, overall economic conditions, general market 
      conditions, price increases of raw materials and components, foreign 
      currency exchange rate fluctuations as well as the risk factors listed 
      from time to time in the SEC filings of E-Z-EM, Inc., including but not 
      limited to its Annual Report on its Form 10-K for the fiscal year ended 
      June 3, 2006 and its Form 10-Q for the quarter ended March 3, 2007. 
      Consequently, actual future results may differ materially from the 
      anticipated results expressed in the forward-looking statements, and 
      investors are cautioned not to place undue reliance on the 
      forward-looking statements included in this release.